Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial

By Emily Hayes / Email the Author / Pharmaceutical Approvals Monthly February 2012, Vol. 17, No. 2
R&D News / Word Count: 687 / Article # 06120201020

Executive Summary

Pfizer’s NDA for dual Src and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML bypassed the failed first-line Phase III BELA trial. In Europe, BELA is the basis of a pending front-line CML application.

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 687-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Pharmaceutical Approvals Monthly will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 3

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article